KR900017977A - 폴리에틸렌 글리콜 유도체, 변성된 펩티드 및 그 제조방법 - Google Patents

폴리에틸렌 글리콜 유도체, 변성된 펩티드 및 그 제조방법 Download PDF

Info

Publication number
KR900017977A
KR900017977A KR1019890006123A KR890006123A KR900017977A KR 900017977 A KR900017977 A KR 900017977A KR 1019890006123 A KR1019890006123 A KR 1019890006123A KR 890006123 A KR890006123 A KR 890006123A KR 900017977 A KR900017977 A KR 900017977A
Authority
KR
South Korea
Prior art keywords
modified
polyethylene glycol
phenylglyoxal
monomethoxypolyethyleneglycol
peptide
Prior art date
Application number
KR1019890006123A
Other languages
English (en)
Inventor
아키히코 사노
히로오 마에다
요시쿠키 카이
게이이치 오노
Original Assignee
스스무 이사오
스미토모 야쿠힝 가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스스무 이사오, 스미토모 야쿠힝 가부시기가이샤 filed Critical 스스무 이사오
Publication of KR900017977A publication Critical patent/KR900017977A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/323—Polymers modified by chemical after-treatment with inorganic compounds containing halogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/064—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for omega-amino or -guanidino functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3344—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur
    • C08G65/3346—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur having sulfur bound to carbon and oxygen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polyethers (AREA)

Abstract

내용 없음

Description

폴리에틸렌 글로콜 유도체, 변성된 펩티드 및 그 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 하기 일반식의 폴리에틸렌 글리콜유도체;
    상기식에서, R은 수평균분자량이 약 1000-12,000의 폴리에티렌 글리콜부인 저급알킬이며, n는 임의의 양의 정수를 나타낸다.
  2. 제1항에 있어서, 4-모노메톡시에틸렌글리콜-페닐글리옥살인 폴리에틸렌 글리콜 유도체.
  3. 구아니디노기가 제1항의 폴리에틸렌 글리콜로 변성된 변성 펩티드.
  4. 제3항에 있어서, 4-모노메톡시폴리에틸렌글리콜-페닐글리옥살로 변성된 플라즈미노겐활성체, 4-모노메톡시폴리에틸렌글리콜-페닐글리옥살에 의해 변형된 성장 호르몬-방출인자, 4-모노메톡시폴리에틸렌글리콜-페닐글리옥살로 변성된 과립구 대식세포 염색체-자극인자, 4-모노메톡시폴리에틸렌글리콜-페닐글리옥살로 변형된 슈퍼옥사이드 분자변위보효소, 및 4-모노메톡시폴리에틸렌글리콜-페닐글리옥살로 변경된 인슐린형태의 성장인자중으로 부터 선택되는 변성펩티드.
  5. 제1항의 폴리에틸렌글리콜 유도체를 구아니디노기를 가진 펩티드와 반응시키는 것으로 구성되는 변성펩티드의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890006123A 1988-05-06 1989-05-04 폴리에틸렌 글리콜 유도체, 변성된 펩티드 및 그 제조방법 KR900017977A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11093188 1988-05-06
JP63-110931 1989-05-06

Publications (1)

Publication Number Publication Date
KR900017977A true KR900017977A (ko) 1990-12-20

Family

ID=14548232

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890006123A KR900017977A (ko) 1988-05-06 1989-05-04 폴리에틸렌 글리콜 유도체, 변성된 펩티드 및 그 제조방법

Country Status (5)

Country Link
US (1) US5093531A (ko)
EP (1) EP0340741A3 (ko)
JP (1) JP2958019B2 (ko)
KR (1) KR900017977A (ko)
CA (1) CA1335722C (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5578496A (en) * 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
WO1993012145A1 (en) * 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
WO1995000162A1 (en) * 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
JP4465109B2 (ja) 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
AU2001280096B2 (en) 2000-08-11 2007-03-22 Kyowa Kirin Co., Ltd. Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAs encoding the same
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
DE60223499T2 (de) * 2001-02-20 2008-10-16 Enzon, Inc. Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate
CA2450985A1 (en) * 2001-06-28 2003-01-09 Mountain View Pharmaceuticals, Inc. Polymer stabilized proteinases
CN100519584C (zh) 2001-12-28 2009-07-29 麒麟医药株式会社 抗成纤维细胞生长因子23的抗体
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2004110345A2 (en) * 2002-10-29 2004-12-23 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
US7498415B2 (en) 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
WO2006019950A2 (en) * 2004-07-16 2006-02-23 Nektar Therapeutics Al, Corporation Conjugates of a gm-csf moiety and a polymer
WO2006054589A1 (ja) * 2004-11-18 2006-05-26 Terumo Kabushiki Kaisha 医薬組成物、製剤および組み合わせ製剤
US20070092482A1 (en) * 2005-08-04 2007-04-26 Bossard Mary J Conjugates of a G-CSF moiety and a polymer
WO2007066698A1 (ja) 2005-12-06 2007-06-14 Kyowa Hakko Kogyo Co., Ltd. 抗ｐｅｒｐ遺伝子組換え抗体
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
JPWO2008114733A1 (ja) 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
AU2008332296A1 (en) 2007-12-05 2009-06-11 Kyowa Hakko Kirin Co., Ltd. Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
WO2009073977A1 (en) * 2007-12-13 2009-06-18 Biovectra Inc. Polypeptides modified by protein trans-splicing technology
WO2010001908A1 (ja) 2008-06-30 2010-01-07 協和発酵キリン株式会社 抗cd27抗体
CN103172735B (zh) 2008-07-17 2014-12-10 协和发酵麒麟株式会社 抗-系统asc氨基酸转运蛋白2(asct2)抗体
EP2331139B1 (en) * 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
PL2374883T3 (pl) 2008-12-26 2017-05-31 Kyowa Hakko Kirin Co., Ltd. Przeciwciało anty-CD4
HUE028537T2 (en) 2009-04-20 2016-12-28 Kyowa Hakko Kirin Co Ltd Built-in amino acid mutation IgG2 antibody
JP5820800B2 (ja) 2010-03-02 2015-11-24 協和発酵キリン株式会社 改変抗体組成物
ES2682078T3 (es) 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
AU2012274461A1 (en) 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
EP2868667B1 (en) 2012-07-02 2019-01-30 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient
TWI614266B (zh) 2012-12-07 2018-02-11 Kyowa Hakko Kirin Co Ltd 抗ｆｏｌｒ１抗體
US11912775B2 (en) 2017-07-18 2024-02-27 Kyowa Kirin Co., Ltd. Anti-human CCR1 monoclonal antibody
CA3081854A1 (en) 2017-11-08 2019-05-16 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to cd40 and epcam
TW202039581A (zh) 2018-12-28 2020-11-01 日商協和麒麟股份有限公司 與TfR結合之雙專一性抗體
JP7502281B2 (ja) 2019-05-15 2024-06-18 協和キリン株式会社 Ｃｄ４０とｇｐｃ３に結合するバイスペシフィック抗体
CA3140385A1 (en) 2019-05-15 2020-11-19 Kyowa Kirin Co., Ltd. Bispecific antibody binding to cd40 and fap
KR20240049285A (ko) 2021-08-26 2024-04-16 쿄와 기린 가부시키가이샤 Cd116 및 cd131에 결합하는 이중 특이적 항체
WO2023153471A1 (ja) 2022-02-09 2023-08-17 国立研究開発法人医薬基盤・健康・栄養研究所 Ｆｃｒｌ１に結合する抗体又は該抗体断片

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof

Also Published As

Publication number Publication date
US5093531A (en) 1992-03-03
JP2958019B2 (ja) 1999-10-06
JPH02117920A (ja) 1990-05-02
EP0340741A2 (en) 1989-11-08
EP0340741A3 (en) 1991-07-03
CA1335722C (en) 1995-05-30

Similar Documents

Publication Publication Date Title
KR900017977A (ko) 폴리에틸렌 글리콜 유도체, 변성된 펩티드 및 그 제조방법
KR960022610A (ko) 아크릴아미드계 또는 메타크릴아미드계 양이온 변성 공중합체, 상기 공중합체를 함유하는 대전방지제, 열가소성 수지 조성물, 수성 조성물 및 열가소성 수지 적층체
KR840009031A (ko) 니모디핀-함유 제제의 제조방법
KR900003163A (ko) 시클로헥산 유도체
KR910000896A (ko) 성형가능한 혼련된 수지 조성물
DE69116381D1 (de) Polymermischungen für wässrige dispersionen mit verbesserter gefrier-auftau-stabilität
EP0400486A3 (en) Polyethylene glycol derivatives, modified peptides and production thereof
KR850700140A (ko) 펜던트 옥사졸린 그룹을 갖는 중합체를 함유하는 중합체 혼합물
KR900004728A (ko) 부티닐아민 유도체
KR920021141A (ko) 갈륨 화합물
KR927003488A (ko) 술폰화제 및 술폰화법
KR910016775A (ko) 방향족비닐화합물 중합용촉매 및 방향족비닐화합물 중합체의 제조방법
KR890016080A (ko) 용융상태에서 광학 이방성을 나타내는 폴리에스테르 수지와 그 조성물
KR910005846A (ko) 치약 조성물
KR890016079A (ko) 용융상태에서 이방성을 나타내는 폴리에스테르 수지와 그것의 조성물
KR910011772A (ko) 나프틸술포닐 알칼산 화합물
PT893121E (pt) Solucao medicinal liquida oral
KR910005860A (ko) 항간질환성 조성물
KR900003200A (ko) 펩티드 유도체 및 항치매제
ATE103965T1 (de) Treibstoffadditivzusammensetzung.
KR900012902A (ko) 에스테르형 중합체성 퍼옥시드류
KR920002215A (ko) 분말의 응집 방지법
KR830000198A (ko) [1-옥소-2-아릴 또는 티에닐-2-치환-5-인다닐옥시(또는 티오)]알카노익 애시드의 제법
KR900003201A (ko) 펩티드 및 항치매제
KR910011952A (ko) 코폴리에스테르 탄성중합체

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee